Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

RESILIENCE

Financiado

Rediscovering the Wanderer: restoration of sympathico-vagal disbalance in irrita...

Rediscovering the Wanderer: restoration of sympathico-vagal disbalance in irritable bowel syndrome by neuromodulation – a novel therapeutic concept Common colloquial phrases like ‘gut feeling’ or ‘butterflies in my belly’ are not just idioms but reflect on the unique communication between gut and brain. The principal interface for this interaction is the autonomic nervous sys... ver más

30/04/2028

UNIVERSITEIT MAAST...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

UNIVERSITEIT MAASTRICHT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 1 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-03-29

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2022-STG: ERC STARTING GRANTS

I+D

Cerrada hace 2 años

0% 100%

1 Participantes

UNIVERSITEIT MAASTRICHT

1.50M€ | Lider

Proyectos interesantes

RIIBS Role of membrane potential Instabilities in Irritable Bowel... 176K€ Cerrado

SAF2009-07416 NEUROFISIOLOGIA Y NEUROFISIOPATOLOGIA DIGESTIVA 218K€ Cerrado

PSI2012-33509 ALTERACIONES NEUROPSICOLOGICAS EN LA FIBROMIALGIA: RELACION... 43K€ Cerrado

PID2019-109612GB-I00 FIBROMIALGIA Y ESTRES POSTRAUMATICO: DESARROLLO DE UN TRATAM... 94K€ Cerrado

PSI2009-09812 EVALUACION PSICOFISIOLOGICA DE LA RESPUESTA AUTONOMICA AL ES... 101K€ Cerrado

DeSTENy SpatioTemporal Diversification of Enteric Nervous system 223K€ Cerrado

Últimas noticias

27-11-2024: Videojuegos y creaci... Se abre la línea de ayuda pública: Ayudas para la promoción del sector del videojuego, del pódcast y otras formas de creación digital

27-11-2024: DGIPYME En las últimas 48 horas el Organismo DGIPYME ha otorgado 1 concesiones

27-11-2024: FUNDACION-EOI En las últimas 48 horas el Organismo FUNDACION EOI ha otorgado 2 concesiones

Duración del proyecto: 61 meses Fecha Inicio: 2023-03-29
Fecha Fin: 2028-04-30

Líder del proyecto

UNIVERSITEIT MAASTRICHT

TRL 4-5

Presupuesto del proyecto 2M€

Descripción del proyecto Common colloquial phrases like ‘gut feeling’ or ‘butterflies in my belly’ are not just idioms but reflect on the unique communication between gut and brain. The principal interface for this interaction is the autonomic nervous system — a largely subconscious system that manages bodily functions through a delicate balance between its two branches: the sympathetic and parasympathetic nervous systems. The vagus nerve is the main component of the latter. Diminished vagal tone resulting in increased sensitivity to pain is characteristic for many chronic pain disorders, including irritable bowel syndrome (IBS). People with IBS have frequent and often severe abdominal pain. While its etiology remains poorly understood, IBS is now assumed to be caused by a malfunctioning of the gut–brain axis, often manifesting in sympathetico–vagal disbalance. However, no established therapies currently target this neurological disturbance. I hypothesize that restoring the sympathico–vagal disbalance through autonomic neuromodulation can be an important novel therapeutic target in IBS. To achieve this, I will use transcutaneous electrical vagus nerve stimulation via the auricular nerve. I will also develop a novel multimodal ‘vagal-autonomic neurosignature’ through combining actively and passively recorded biometrics and high-power field neuroimaging. This profile will allow identification of patients who could benefit from the new treatment approach. Simultaneously, I will investigate mechanisms of action in a comprehensive manner, using experimental models and tools I have previously developed. My project is foreseen to fundamentally change the therapeutic landscape of IBS and other pain disorders by providing high-quality clinical and mechanistic evidence for the efficacy of vagal neuromodulation. Identifying a neurological signature of patients that likely benefit from this approach would represent a major break-through in individualizing therapeutic efforts in IBS.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores